Business
Corxel will use the fundraising proceeds to advance the oral GLP-1 therapy CX11 through mid-stage development in the U.S., as well as prepare for its Phase III studies.
FEATURED STORIES
After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will capture the lion’s share of the market for on-demand use.
Biohaven has suffered a few setbacks in recent months, including an FDA rejection and a missed $150 million benchmark payment, but CEO Vlad Coric looked for the brighter side at JPM, specifically emphasizing a serendipitous discovery that could get the company in the obesity game.
Henry Gosebruch, who has $3.5 billion in capital to deploy, is thinking broad as he steers the decades-old biotech out of years of turmoil.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Biosimulation is integral to drug development today, with fierce competition for expert scientists to run the simulations and interpret the results. Craig Rayner, president of Certara, a biosimulation company, is turning to Africa to unlock an untapped reservoir of talent.
“When big pharma collaborates with biopharma companies, the main risk isn’t the technology, but the commitment of the partner,” according to serial entrepreneur Yochi Slonim, CEO of Anima Biotech. That isn’t merely his opinion. The question arises in partnering meetings routinely.
Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.
For the past year, Abbott Laboratories and Quest Diagnostics saw their revenue driven by COVID-19 diagnostics, but that seems to be changing as more and more vaccinated individuals are seeking medical advice for non-viral related issues.
Biotech company Slingshot Biosciences announced Thursday it had closed a $23 million Series A financing round led by Northpond Ventures.
The last several years have marked several attempts to stimulate life sciences startups to pick the Big Apple.
The life sciences is always a frenetic sector when it comes to mergers & acquisitions, initial public offerings (IPOs) and Series A announcements (not to mention B and C rounds). But during the second quarter of 2021, these companies were especially busy bees – all positive signs that the industry is still booming coming out of the COVID-19 pandemic.
This week the pharma giant announced a second collaboration agreement with Connecticut-based Arvinas to develop and commercialize its PROTAC estrogen receptor protein degrader.
Mirimus and Biogen, AavantiBio and Aldevron, Exscientia and GT Apeiron Therapeutics announced strategic partnerships this morning.
More money means more progress for potentially life-saving therapies. Here’s a peek at some biopharma companies adding to their books this week.